



A Cell-Surface GH9 Endo-Glucanase Coordinates with Surface Glycan-Binding Proteins to Mediate Xyloglucan Uptake in the Gut Symbiont *Bacteroides ovatus*

Matthew H. Foley¹, Guillaume Déjean², Glyn R. Hemsworth³, Gideon J. Davies³, Harry Brumer^{2,4,5} and Nicole M. Koropatkin¹

1 - Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA

2 - Michael Smith Laboratories, University of British Columbia, 2185 East Mall, Vancouver, BC V6T 1Z4, Canada

3 - York Structural Biology Laboratory, Department of Chemistry, University of York, Heslington, York YO10 5DD, UK

4 - Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada

5 - Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada

Correspondence to Nicole M. Koropatkin: nkoropat@umich.edu

<https://doi.org/10.1016/j.jmb.2019.01.008>

Edited by Thomas J. Smith

Abstract

Dietary fiber is an important food source for members of the human gut microbiome. Members of the dominant Bacteroidetes phylum capture diverse polysaccharides via the action of multiple cell surface proteins encoded within polysaccharide utilization loci (PUL). The independent activities of PUL-encoded glycoside hydrolases (GHs) and surface glycan-binding proteins (SGBPs) for the harvest of various glycans have been studied in detail, but how these proteins work together to coordinate uptake is poorly understood. Here, we combine genetic and biochemical approaches to discern the interplay between the BoGH9 endoglucanase and the xyloglucan-binding proteins SGBP-A and SGBP-B from the *Bacteroides ovatus* xyloglucan utilization locus (XyGUL). The expression of BoGH9, a weakly active xyloglucanase in isolation, is required in a strain that expresses a non-binding version of SGBP-A (SGBP-A*). The crystal structure of the BoGH9 enzyme suggests the molecular basis for its robust activity on mixed-linkage β -glucan compared to xyloglucan. However, catalytically inactive site-directed mutants of BoGH9 fail to complement the deletion of the active BoGH9 in a SGBP-A* strain. We also find that SGBP-B is needed in an SGBP-A* background to support growth on xyloglucan, but that the non-binding SGBP-B* protein acts in a dominant negative manner to inhibit growth on xyloglucan. We postulate a model whereby the SGBP-A, SGBP-B, and BoGH9 work together at the cell surface, likely within a discrete complex, and that xyloglucan binding by SGBP-B and BoGH9 may facilitate the orientation of the xyloglucan for transfer across the outer membrane.

© 2019 Elsevier Ltd. All rights reserved.

Introduction

The Bacteroidetes phylum is a ubiquitous and dominant inhabitant of the human gut [1]. *Bacteroides thetaiotaomicron* and *Bacteroides ovatus*, two representative species, devote ~20% of their genomes to encoding proteins with functions involved in carbohydrate catabolism [2]. Members of the Bacteroidetes encode a diverse array of glycoside hydrolases (GHs) compared to other members of the gut microbiota, and these impart their broad capacity for glycan degradation [3,4]. These GH genes are organized within discrete gene clusters termed polysaccharide

utilization loci (PUL) that also express gene products for glycan capture and import. Individual PUL are transcriptionally stimulated in the presence of their cognate glycan [5,6]. A noteworthy feature of each PUL is the presence of two genes whose products are homologous to proteins within the starch utilization system (Sus) of *B. thetaiotaomicron*: SusC, a putative TonB-dependent transporter (TBDT) and SusD, a cell surface glycan-binding protein (SGBP). Additional SGBPs are also often encoded within PUL and contribute to glycan capture at the cell surface, but the precise roles of these proteins are variable and substrate-dependent [7–9].

B. ovatus dedicates one of its PUL to the uptake of xyloglucans (XyGs) [10], a family of prominent plant cell wall polysaccharides in commonly consumed vegetables such as tomato, lettuce, and peppers [11]. XyGs contain a $\beta(1,4)$ -linked glucan backbone that is decorated with $\alpha(1,6)$ xylosyl substitutions. Depending on the source, these xylose chains can be extended with additional monosaccharides such as galactose, fucose, and arabinose [11–13]. XyG is an important glycan to the human gut microbiota, as underscored by the observation that ~92% of human microbiomes contain PULs homologous to the *B. ovatus* xyloglucan utilization locus (XyGUL) [10].

The *B. ovatus* XyGUL contains 112 genes responsible for the capture, import, and complete degradation of

XyG (Fig. 1). Most of the individual GH and SGBP components of this PUL have been structurally and functionally characterized, making this an important model system for understanding polysaccharide recognition and degradation by the Bacteroidetes [8,10,14]. Within the XyGUL, five genes encode outer-membrane proteins that initiate XyG utilization at the cell surface: a SusD-like protein (SGBP-A), an additional SGBP (SGBP-B) that mediates substrate binding, a GH9 (BoGH9), a GH5 endo-xyloglucanase (BoGH5A) that performs initial polysaccharide backbone cleavage, and a membrane-spanning SusC-like TBDT that is responsible for import of product oligosaccharides to the periplasm. Additional structural and biochemical analysis of the six periplasmic GHs




Fig. 1. Overview of the XyGUL in *B. ovatus*. Xyloglucan is bound by the XyG-binding proteins SGBP-A and SGBP-B, and the endo-glucanases BoGH5A and BoGH9 cleave along the polysaccharide backbone to generate XyG oligosaccharides that can be imported into the cell by the TBDT. Two α -arabinofuranosidases (GH43A/B), one β -galactosidase (GH2), one α -xylosidase (GH31), and two β -glucosidases (GH3A/B) disassemble these oligosaccharides into monosaccharides that enter the cytoplasm through an unknown transporter. A hybrid two-component system (HTCS)-like regulator senses an unknown XyG-derived substrate that leads to the activation of XyGUL transcription.

has contributed to a holistic understanding of XyG disassembly into monosaccharides for cytosolic uptake and metabolism [10,14].

An outstanding question regarding the XyGUL is the function of the cell surface BoGH9. Notably, the *B. ovatus* XyGUL is the only XyGUL identified thus far that includes a GH9 member, and our previous study indicated that the very weak endo-(xylo)glucanase activity measured for BoGH9 was insufficient to support growth in the absence of the vanguard BoGH5A endo-xyloglucanase [10]. These observations led us to hypothesize that BoGH9 may have evolved toward a non-catalytic, substrate-binding function, possibly working in conjunction with the SGBPs [15]. Using a combination of structural enzymology of BoGH9 and combinatorial reverse genetics with the SGBP components of the XyGUL, we demonstrate here that synergy among these cell surface proteins facilitates XyG capture and import, likely arising from interactions within a discrete multi-protein complex. More generally, our findings provide further understanding of how collaborative protein–protein and protein–carbohydrate interactions affect the utilization of common dietary glycans by a key member of the gut microbiota.

Results

We recently determined the crystal structures of the XyGUL SGBP-A, SGBP-B, and BoGH5A and demonstrated that in-frame deletions of SGBP-A or BoGH5A from the *B. ovatus* genome abolish XyG utilization [8,10]. However, complementation of the Δ SGBP-A strain with a site-directed mutant allele encoding for SGBP-A that cannot bind XyG (SGBP-A*) restores growth on XyG. Moreover, *B. ovatus* expressing SGBP-A* but lacking SGBP-B displays wild-type exponential growth on XyG, suggesting that glycan binding by the SGBPs is not their sole function. These findings parallel our work on the Sus of *B. thetaiotaomicron* in which we demonstrated that a binding-deficient allele of the SGBP-A homolog SusD (SusD*) supports growth on maltooligosaccharides when co-expressed with the starch-binding deficient SGBP allele, SusE*. Together these data support that glycan binding by SGBPs may be of secondary importance to glycan utilization, while the presence of these proteins for the formation of a complex around the TBDT is primary [7,16]. Indeed, the crystal structures of two TBDT–SusD-like complexes, BT2261–2264 and BT1762–1763, demonstrate that the SusD/SGBP-A homologs close over the top of and likely guide their substrate-binding site into, their cognate TBDT [17]. That purification of BT2261–2264 included the SGBPs BT2261–2262 supports the idea that these glycan-capturing complexes may be influenced by multiple SGBP interactions beyond the cognate TBDT–SusD/SGBP-A pair.

Structure of the XyGUL GH9

We previously determined the crystal structures of the BoGH5A and the two SGBPs of the XyGUL [8,10]. Therefore, to resolve a gap in our understanding of the structural biology of the XyGUL, and as a prelude to further biochemical and reverse genetic studies, we obtained a tertiary structure of recombinant BoGH9 by X-ray crystallography. The 1.4-Å structure of BoGH9 ($R_w = 16.8\%$, $R_f = 19.7\%$; Table 1) is composed of two domains: an N-terminal Ig-like fold (residues 27–115) followed by the catalytic domain that has a canonical $(\alpha/\alpha)_6$ fold typical of this GH family (Fig. 2A). The final model was composed of residues 27–583, with only a surface loop (residues 535–545) that could not be resolved in the density.

The closest structural homologs of BoGH9 from a DALI search [18] are *Clostridium thermocellum* CelD [CtCelD; Protein Data Bank (PDB) ID 4CJ1, $Z = 46.5$] [19], *Alicyclobacillus acidocaldarius* cellulase Cel9A (AaCel9A; PDB ID 3GZK, $Z = 46.2$) [20], and a metagenomic cellulase (PDB ID 3X17, $Z = 45.5$). Both CtCelD and AaCel9A are well-characterized cellulases [21,22] and can be superimposed onto the

Table 1. X-ray data collection and refinement statistics for BoGH9

PDB	6DHT
Wavelength (nm)	0.979
Resolution range (Å)	44.74–1.42 (1.47–1.42)
Space group	C2
	$a = 130.65$, $b = 50.41$, $c = 95.98$, $\beta = 109^\circ$
Unit cell (Å)	
Total reflections	731,375 (48,647)
Unique reflections	109,840 (9432)
Multiplicity	6.7 (5.2)
Completeness (%)	98.30 (84.59)
Mean $\ \sigma(I) \ $	21.0 (2.1)
Wilson B -factor	16.0
R_{merge}	0.081 (0.59)
R_{meas}	0.088
CC1/2	0.996 (0.841)
CC*	0.999 (0.956)
Reflections used for R_{free}	1898
R_{work}	0.167 (0.28)
R_{free}	0.197 (0.31)
Number of non-hydrogen atoms	4957
Macromolecules	4344
Ligands	87
Water	526
Protein residues	547
RMS (bonds)	0.009
RMS (angles)	1.28
Ramachandran favored (%)	96
Ramachandran outliers (%)	0.18
Clashscore	3.22
Average B -factor	
All atoms	23.6
Macromolecules	22.3
Ligands	33.8
Solvent	33.4

Parentheses indicate statistics for the highest-resolution shell.




Fig. 2. Crystal structure of BoGH9 with imidazole. Ribbon cartoon of the BoGH9 backbone, colored blue to red from the N- to C-terminus. Two calcium ions are displayed as large black spheres, and the magnesium is displayed as a smaller black sphere. An imidazole that was trapped in the active site cleft is displayed as pink and blue spheres. The N- and C-termini are labeled, as is the end of a disordered loop (residues 535–544) that could not be resolved. (B) Close-up view of the imidazole in the active site. Protein is displayed with $12F_o - F_c$ density contoured at $\sigma = 1.3$, and omit density for the imidazole is contoured at 3.0σ . A PEG molecule (yellow) from the crystallization liquor is also displayed. (C and D) Coordination spheres of the calcium ions with $12F_o - F_c$ density contoured at 1.5σ . (E) Divergent overlay of the BoGH9 active site (green) with the AaCel9A (3H3K) active site (gray sticks) that has cellotetraose and glucose (yellow sticks). Imidazole in the BoGH9 structure is displayed as magenta and blue sticks.

BoGH9 structure with RMSD values of ~ 1.0 Å for 378 and 366 C α atom pairs, respectively. The combination of an Ig-like N-terminus preceded by a catalytic domain places BoGH9 within the Type C class of GH9 [23], akin to AaCel9A.

Within the active site cleft of BoGH9, an imidazole and PEG molecule from the crystallization liquor were captured (Fig. 2B). In addition, density was observed in other parts of the protein that represented two calcium ions and one magnesium ion, both of which were

included in the crystallization liquor (as $MgCl_2$ and $CaCl_2$, respectively). The calcium ions are coordinated primarily by amino acid side chains and display the expected octahedral geometry and atomic distances (~ 2.4 Å) for this metal (Fig. 2C, D). Conversely, the magnesium ion is coordinated near the surface of the enzyme by two aspartates and three water molecules, with coordination distances of ~ 2.1 Å. Its presence here may be serendipitous, due to the inclusion of magnesium in the crystallization. Indeed, the coordinating residues of all three ions are conserved in the structure of the *C. thermocellum* CelD (CtCelD) and capture calcium atoms [19]. These divalent cations are thought to lend structural stability to the enzyme, and none are involved directly in catalysis [24].

Comparison of the BoGH9 structure with that of AaCel9A complexed with cellotetraose and glucose (PDB 3H3K, Z-score 50.8 between catalytic domains, Supplemental Fig. 1) reveals structural homology within the active site (Fig. 2E). Notably, the binding of the imidazole (a known inhibitor of some β -glucosidases [25,26], here present in high concentration, ~ 50 mM, in the crystallization buffer), between the $-1/-2$ subsites results in several changes in the orientation of active site residues in BoGH9 compared to AaCel9A. The N atoms of imidazole are coordinated by Y347 and the catalytic acid E562. W451 and Y558 swing toward the imidazole to create a more hydrophobic environment, although neither provides a direct stacking interaction. The equivalent residues in AaCel9A, W401, and Y511 provide a hydrophobic platform to position glucose residues at the -2 and $+1$ subsites [20]. Of the 19 residues that create the active site cleft in AaCel9A, only 4 are not conserved in BoGH9. Two of these residues are G390 and N391 in BoGH9 (A344 and D345 in AaCel9A), which are proximal to the putative -3 and -4 subsites but do not directly bind substrate in AaCel9A. F450 of BoGH9 is homologous to I400 in AaCel9A and Y456 of CtCelD within the -4 subsite; the substitution to a Phe in BoGH9 may better support substrate interaction. Likewise, in both the BoGH9 structure and CtCelD, an Asn (as N566 in BoGH9) is occupied by Y519 in AaCel9A near the -2 subsite. Overall, BoGH9 demonstrates a high degree of structural similarity with these representative GH9 members, most notably including a narrow active-site cleft that reflects its poor tolerance of the branched β -glucan XyG (vide infra).

Regarding the disordered loop in BoGH9 extending from residues 535–545, neither the CtCelD nor a homologous metagenomic cellulase (PDB 3X17) displays an extended surface loop in this region. However, the AaCel9A has a loop composed of H485–G497 that shapes the $-3/-4$ subsites of the active site. In AaCel9A, H485 and Q487 provide hydrogen-bonding coordination with the hydroxyls of adjacent glucose residues. In the equivalent loop of BoGH9, G535 replaces H485, but Q537 has the same position in the sequence as Q487 of AaCel9A. The

remainder of this loop sequence is not conserved between BoGH9 and AaCel9A, and the significance for activity is unknown. However, the flexibility of this loop in BoGH9, inferred from its lack of density, suggests that it is unlikely to block access to the active site and restrict activity or substrate selection.

BoGH9 has substantial calcium-dependent activity on mixed-linkage β -glucans

Our previous kinetic analysis of recombinant BoGH9 revealed that the enzyme was catalytically feeble toward XyG, as well as other β -glucans. In light of the BoGH9 crystal structure and the previous report that CtCelD of GH9 requires calcium for activity [22], we revisited the enzymology of BoGH9. As observed previously [10], recombinant BoGH9 has very weak and equally poor activity on the representative β -glucans, mixed-linkage $\beta(1-3)/\beta(1-4)$ -glucan (MLG), hydroxyethylcellulose (HEC), carboxymethylcellulose (CMC), and XyG in the absence of the addition of Ca^{2+} to the assay (Table 2, see Supplemental Fig. 2 for carbohydrate structures). BoGH9 displays 400-fold lower specific activity toward XyG (0.042 ± 0.012 $\mu\text{mol}/\text{min}/\text{mg}$, Table 2) than the vanguard endo-xyloglucanase of the XyGUL, BoGH5A (9.3 ± 0.6 $\mu\text{mol}/\text{min}/\text{mg}$). In the presence of 1 mM Ca^{2+} , the specific activity of BoGH9 toward XyG remains essentially unchanged (2-fold increase), while, strikingly, the specific activity toward MLG increases 8.5-fold (Table 2). The specific activities of BoGH9 toward the artificial substrates HEC and CMC are likewise increased, 5.5- and 3.8-fold, respectively, in the presence of Ca^{2+} .

Product analysis revealed that, similar to BoGH5A, BoGH9 cleaves the XyG backbone endo-hydrolytically to ultimately yield XyGO₁, the natural distribution of variably galactosylated Glc₄-backbone-based hepta- to nonasaccharides from tamarind seed XyG (Supplemental Fig. 3). BoGH9 hydrolyzes MLG to the mixed-linkage tetrasaccharides G3G4G4G, G4G3G4G, and G4G4G3G, which is distinct from the exclusive G4G4G3G product specificity of GH16 MLGases [27]. Notably, G3G4G4G was ultimately hydrolyzed to

Table 2. Activity of BoGH9 against different polysaccharide substrates^a

Enzyme	Substrate	Specific activity, $\mu\text{mol} (\text{min mg})^{-1}$	Specific activity (with Ca^{2+} 1 mM), $\mu\text{mol} (\text{min mg})^{-1}$
BoGH9	MLG	0.042 ± 0.012	0.36 ± 0.05
	XyG	0.023 ± 0.003	0.05 ± 0.01
	HEC	0.027 ± 0.004	0.15 ± 0.05
	CMC	0.021 ± 0.001	0.08 ± 0.01

^a Assays conducted in Hepes–NaOH at pH 7.0. Recombinant enzymes were incubated at 37 °C with the different tested substrates.

G3G4G in the limit digest. All $\beta(1-4)$ linked cello-oligosaccharides were not produced, indicating that BoGH9 does not cleave the $\beta(1-3)$ -linkages in MLG (Supplemental Fig. 3).

Examination of complexes in which MLG and XyG oligosaccharide fragments were manually docked into the BoGH9 apo structure indicated the structural basis for the observed substrate specificity of the enzyme. Indeed, a BoGH9:XyGO complex could not be definitively modeled due to significant steric clashes of highly branched oligosaccharides (e.g., from PDB ID 3ZMR) with side chains of BoGH9 in the active-site cleft (Supplemental Fig. 4A). Modeling of the MLG oligosaccharide G4G3G (e.g., from PDB ID 1ZM1) into the BoGH9 active site was more favorable, despite the differences in the position of the $-2/-3$ subsites imposed by the $\beta 1,3$ linkage (Supplemental Fig. 4B). Compared to the conformation of the enzyme in our structure with imidazole, productive BoGH9 and substrate binding likely requires a significant rearrangement of the active site.

BoGH9 is required for growth on XyG in an SGBP-A* strain

The poor activity of BoGH9 toward XyG, even in the presence of calcium, is concordant with the inability of this enzyme to confer growth of *B. ovatus* on the polysaccharide in the absence of BoGH5A [10]. We therefore hypothesized that BoGH9 could play a role in XyG capture rather than degradation, perhaps working in harness with the SGBPs at the cell surface. To test this, we created a set of in-frame deletions and/or point mutant alleles of the BoGH9 and SGBP-B genes in a genetically manipulatable *B. ovatus* Δtdk strain, hereafter referred to as wild-type [10]. In particular, we designed a series of variants to completely ablate substrate binding by removal of key aromatic side chains in the SGBPs, referred to as SGBP-A* and SGBP-B*, as well as inactive, catalytic residue variants of BoGH9 (Table 3). Mutant strains were passaged overnight in minimal media (MM) containing glucose, then back-diluted 1:200 into parallel cultures containing glucose, xylose, XyGOs, or XyG prior to monitoring growth in liquid culture. The XyGUL is not required for growth on glucose [10] or xylose, and none of our mutants demonstrated a kinetic growth defect or apparent difference in lag on these monosaccharides (Supplemental Fig. 5).

While a single in-frame deletion of the gene encoding BoGH9 does not affect growth on XyG or XyGO₂ (the natural distribution of Glc₈-backbone-based oligosaccharides from tamarind XyG, Supplemental Fig. 2) [10], a strain containing a combined SGBP-A*/ Δ BoGH9 mutation could no longer grow on any of the XyG substrates tested (Fig. 3B–E). However, this phenotype could be rescued by complementation of the native BoGH9 gene within the operon (Supplemental Fig. 6). A strain lacking all

Table 3. Mutant XyGUL alleles used in this study

Mutant allele	Mutations (by protein residue number)	Effect	Reference
SGBP-A*	W82A, W283A, W306A	No XyG binding	[8]
SGBP-B*	Y363A, W364A	No XyG binding	[8]
BoGH9 ^{D185N}	D185N	Catalytic base mutant	This study
BoGH9 ^{D185A}	D185A	Catalytic base mutant	This study
BoGH9 ^{E562Q}	E562Q	Catalytic acid mutant	This study
BoGH9 ^{E562A}	E562A	Catalytic acid mutant	This study

potential XyG-binding sites (SGBP-A*/ Δ SGBP-B/ Δ BoGH9) was likewise unable to grow on any XyG or XyGO substrate tested. It should be noted here that we have used SGBP-A* variants instead of the corresponding Δ SGBP-A variants, because deletion of the protein ablates growth on XyG, likely due to an intimate structural interaction with the TBDT of the XyGUL [8,17]. Interestingly, the Δ BoGH9 mutation alone was sufficient to produce a kinetic growth defect on XyGO₁, similar to the SGBP-A* mutation (Fig. 3C and E), whereas on XyG and XyGO₂, there was no significant difference from wild-type for either mutant strain (Fig. 3B and D). These phenotypes suggest that both SGBP-A and BoGH9 play similarly important roles in XyG/XyGO capture, and that when both of these proteins are simultaneously absent, saccharide uptake is too inefficient to support growth.

The observation that a GH can complement the loss of an SGBP has not been observed previously in PUL systems, to our knowledge. To test whether the enzymatic activity of BoGH9 was required to compensate for the SGBP-A* mutation, we mutated the catalytic residues inferred from the tertiary structure, D185 and E562, to generate four independent *B. ovatus* strains (Table 3). Recapitulating the Δ BoGH9 strain phenotype, growth of the BoGH9^{D185N} strain on XyGO₁ was noticeably slower (Fig. 3C, E), while growth on XyG and XyGO₂ was indistinguishable from the wild-type (Fig. 3B and D). Analogous to the SGBP-A*/ Δ BoGH9 strain, the SGBP-A*/BoGH9^{D185N} strain was not able to grow on any of the XyG substrates tested (Fig. 3B–E). Identical growth defects on XyG were obtained with the other catalytically inactive variants (Supplemental Fig. 6). As observed for the Δ BoGH9 strain, none of the four active-site-directed mutant alleles interfered with growth on XyG in a wild-type background (Supplemental Fig. 6). Western blot analysis using anti-BoGH9 antibodies confirmed that all BoGH9 variants were expressed at similar levels (Supplemental Fig. 6D). Together, these data indicate that both the presence of BoGH9 and its enzymatic activity are required for polysaccharide utilization in the absence of a functional SGBP-A.




Fig. 3. BoGH9 capture of XyG compensates for the loss of XyG binding by SGBP-A. Growth of BoGH9 mutants on 5 mg/ml (A) glucose, (B) XyG, (C) XyGO₁, (D) XyGO₂, and (E) Specific growth rate of select strains on XyGO₁ at O.D.₆₀₀ = 0.5. (F) Strain legend for panels A–E. In panels B–D, the strains that do not display growth are SGBP-A*/ΔBoGH9 (blue), SGBP-A*/ΔSGBP-B/BoGH9 (brown), and SGBP-A*/BoGH9^{D185N} (black).

SGBP-B* antagonizes growth on XyG in an SGBP-A* background

The dependence of a catalytically competent BoGH9 in the SGBP-A* background was surprising and prompted us to re-examine how the other non-catalytic XyG-binding protein, SGBP-B, contributes to growth [8]. We previously reported that a ΔSGBP-B strain grows like wild-type on XyG and XyGOs, but a SGBP-A*/ΔSGBP-B strain displays a severe apparent

lag (Fig. 6 in Ref. [8], and Fig. 4). Here, we extended our previous analysis by replacing the native SGBP-B with the XyG-binding deficient allele SGBP-B* (Table 3) in *B. ovatus* expressing wild-type SGBP-A or the binding deficient allele SGBP-A*, to determine the specific contribution of the SGBP binding site to growth. While the ΔSGBP-B and SGBP-B* strains grew normally on both XyG and XyGO₂ (Fig. 4B, D), a combined SGBP-A*/SGBP-B* mutant was completely unable to grow on any XyG or XyGO substrate, which we ascribe to a




Fig. 4. XyG-binding deficient SGBP-B antagonizes growth in the absence of SGBP-A glycan binding. Growth of *B. ovatus* SGBP-B mutants on 5 mg/ml (A) glucose, (B) XyG, (C) XyGO₁, and (D) XyGO₂. (E) Specific growth rate of select strains on XyGO₁ at O.D.₆₀₀ = 0.5. (F) Strain legend for panels A–E. In panels B–D, the SGBP-A*/SGBP-B* strain that cannot grow is colored brown.

dominant-negative effect in which the SGBP-B* protein may interfere with the structural function of the SGBP-A* protein (vide infra).

Isothermal titration calorimetry previously indicated that SGBP-A displays negligible binding for XyGO₁, whereas SGBP-B has a K_d of ~ 400 μ M toward this minimal repeating motif [8]. Consistent with this observation, we previously demonstrated that Δ SGBP-B strains grew less efficiently on XyGO₁ than the SGBP-A* strain [8]. Here, the single SGBP-B* mutant grew comparably to wild-type, whereas the combined mutant SGBP-A*/SGBP-B* could not grow

at all on XyGO₁ (Fig. 4C, E). The complete loss of XyGO₁ growth in the SGBP-A*/SGBP-B* strain demonstrates that at least one functional XyG-binding SGBP is required to support the capture of XyG or its oligosaccharides.

Since SGBP-A*/ Δ SGBP-B but not SGBP-A*/SGBP-B* is capable of growth on XyG, albeit with an apparent lag, we reasoned that the SGBP-B* antagonizes XyG capture when combined with the XyG-binding deficient SGBP-A*. Using a pNBU2 vector modified for anhydrotetracycline (aTC)-inducible gene expression [28], we engineered our parent strain, SGBP-A*, to express

either SGBP-B or SGBP-B* from the *att1* site, which is located outside of the XyGUL [10]. In order to ensure expression of SGBP-B or SGBP-B* during the early time points of the experiment, cultures were pregrown on glucose-containing medium with 2 nM aTC to induce expression and then back-diluted into XyG-containing medium including 2 nM aTC. Inducing the expression of SGBP-B appeared to enhance the start of exponential growth on XyG, likely by priming cells for XyG capture, whereas the expression of SGBP-B* abolished growth of the SGBP-A* similar to the SGBP-A*/SGBP-B* phenotype (Fig. 5, yellow and green lines). Since the native SGBP-B gene remained intact in these experiments, these conditions should not impact the ability of cells to bind to XyG. Rather, the dominant negative effect from early induction of SGBP-B* before exposure to XyG to induce native protein expression may be due to competition within a cell-surface protein complex. Although the XyGUL-encoded SGBP-B protein is expressed to higher levels once cells are exposed to XyG, by inducing early expression of pSGBP-B*, the mutant may outcompete the native protein for a position within the uptake complex. To validate that protein expression was

similar for induction of either SGBP-B or SGBP-B*, we performed a Western blot using anti-SGBP-B antibodies on whole cell lysates (Fig. 5D). Since glucose does not activate expression of the native SGBP-B, we do not detect any SGBP-B in cultures without induction. Induced, glucose-grown cultures expressing aTC-inducible SGBP-B or SGBP-B* display similar levels of the protein, underscoring that the SGBP-B* protein exerts a phenotypic difference that is not due to differing levels of expression between these strains.

Discussion

The regular consumption of dietary fiber is critical for the assembly and preservation of a healthy gut microbiome. Glycans from plant cell walls transit the intestinal tract where they become depolymerized and fermented by members of the microbiota, including the dominant Bacteroidetes [3,29,30]. This influx of carbon and energy into the gut ecosystem influences the composition of the microbiota, as well as its metabolic output [31,32]. Here, we studied the inner workings of a




Fig. 5. Inducible expression of SGBP-B* acts in a dominant-negative fashion to inhibit growth in an SGBP-A* strain. Inducible expression of SGBP-B/B* in an SGBP-A* Δ B background during growth on 5 mg/ml (A) glucose and (B) XyG. The strains in panel B that did not grow are SGBP-A*/SGBP-B* (orange) and SGBP-A* pSGBP-B* + 2 nM aTC (green). (C) Strain legend for panels A and B. (D) Western blot of SGBP-B/B* using anti-SGBP-B serum against whole cell lysates. SGBP-A* strains were cultured in MM containing either 5 mg/ml XyG or glucose, with or without 2 nM aTC, as noted. Cells were arrested in mid-logarithmic phase then normalized by O.D.₆₀₀ before loading equal volumes in SDS-PAGE.

xyloglucan-degrading system in the model organism *B. ovatus* and demonstrated that the enigmatic GH, BoGH9, and the cell SGBP, SGBP-B, impact the transport of xyloglucan in a manner that is dependent on SGBP-A XyG binding. These results imply that the relationships between the XyGUL-encoded cell surface proteins are more complex than previously appreciated, and furthermore suggest that the assembly of a multiprotein complex modulates glycan capture at the cell surface.

BoGH9 appears to also play a role in XyG capture when coexpressed with SGBP-A*. The SGBP-A*/ Δ BoGH9 and SGBP-A*/BoGH9^{D185N} strains were not able to grow on any XyG substrate tested (Fig. 6A). The xylan PUL (PUL-Xyl) of *B. ovatus* encodes a consortium of cell surface enzymes involved in xylan debranching and degradation, but one catalytically

inactive GH10 is predicted to be involved in xylan capture as opposed to hydrolysis [15]. Unlike the PUL-Xyl GH10, BoGH9 requires use of its catalytic machinery in the SGBP-A* mutant, but perhaps, its role in XyG capture is to locally cleave and orient XyG oligosaccharides into the TBDT in the absence of the SGBP-A binding site. Little is known about the assembly, organization, and dynamics of the proteins that form a complex around the XyGUL TBDT. A general model for glycan uptake, informed by the structures of the BT2281–2264 and BT1762–1763 complexes, predicts that SGBP-A may close down over the top of the TBDT with a XyG oligosaccharide in its binding site, thereby coordinating the substrate into the transporter [17]. In an SGBP-A* strain, XyG is still utilized, but the requirement for a catalytically active BoGH9 implies that XyG fragments liberated by the cell




Fig. 6. A Model for xyloglucan uptake facilitated by SGBP-B and BoGH9. Asterisks indicate “*” versions of XyG-binding proteins that can no longer bind XyG. The relative growth of the SGBP-B and BoGH9 mutant strains on xyloglucan is displayed with more + indicating less lag time and more efficient growth. Protein sizes are not to scale and are enlarged when emphasizing proteins of interest. (A) Catalytically active BoGH9 is essential for growth on XyG in the SGBP-A* background. (B) SGBP-B is not necessary for in vitro growth on XyG, but the early induction of SGBP-B* antagonizes growth in a SGBP-A* background.

surface BoGH5A can interact with and are perhaps hydrolyzed by the active site of BoGH9 prior to internalization.

That BoGH9 is only encoded within the XyGUL of *B. ovatus* suggests that this enzyme has been maintained and adapted to facilitate the breakdown of XyGs at the cell surface. Acting broadly on β -glucans is typical of GH9 enzymes, and strict endo-xyloglucanase activity from GH9 has only recently been characterized [33,34]. The structural determinants of the GH9 family that support the specific recognition and hydrolysis of xyloglucan compared to other β -glucans remain unknown [35]. The expanded, albeit poor, activity on a range of β -glucan substrates could make BoGH9 a useful tool when *B. ovatus* forages polysaccharides from plant cell walls rich in cellulose and hemicelluloses. Although most PUL systems contain minimal enzyme cohorts required for their cognate substrates [4,36], the variety of enzyme activities and specificities in the XyGUL may support the liberation of xyloglucan from the plant cell wall. For example, the Gram-positive *Ruminococcus cellulitum* uses a large (>1 MDa) outer-membrane complex of proteins referred to as cellulosomes to bring together multiple GH9 enzymes as well as other endo- and exo-acting β -glucanases to support its catabolism of xyloglucan [34,37,38]. Furthermore, it is possible that the activity of the BoGH9 is enhanced in its native environment at the cell surface by its proximity to the XyG-specific SGBPs, akin to how carbohydrate-binding modules can potentiate enzyme activity within contiguous polypeptides [39].

SGBP-B-like proteins encoded within PUL across the Bacteroides perform a variety of tasks during glycan capture [40]. The SGBP-B-like protein from the heparin/heparan sulfate PUL of *B. thetaiotaomicron* appears to adapt the bacteria for growth on heparin oligosaccharides [41]. SusE and SusF assist the diffusion of starch across the capsular surface for capture [42], and SusE facilitates the effective uptake of maltooligosaccharides ~7–30 glucose units long [7]. SusE was found to interact in a protein complex with SusC and SusD [16], and its proximity to these proteins may impart conformational changes that influence maltooligosaccharide uptake [7]. Here, the most striking phenotype for the deletion of SGBP-B in an otherwise wild-type *B. ovatus* is a kinetic defect in exponential growth on the smallest XyG unit, XyGO₁. Conversely, a non-binding allele, SGBP-B* does not affect growth on XyGO₁ in an otherwise wild-type strain, suggesting that it is not just binding by SGBP-B that is important for the effective capture of this oligosaccharide. When SGBP-B is deleted in conjunction with the binding deficient SGBP-A*, an extended lag is observed on XyG and XyGO₂, while a severe kinetic defect is observed on XyGO₁. However, when binding deficient alleles SGBP-A* and SGBP-B* are co-expressed, cells fail to grow on any XyG substrate (Fig. 6B). We believe that, like SusE during growth on starch [7], SGBP-B performs addi-

tional functions outside of binding and sequestering XyG at the cell surface and that this may be related to its interaction with the TBDT. Given the observation that the ectopic expression of SGBP-B* in the SGBP-A* mutant inhibits growth despite the presence of the wild-type SGBP-B, SGBP-B* may be outcompeting SGBP-B for an interaction near the XyGUL TBDT. Outside of the XyGUL, additional PUL-encoded surface lipoproteins like SGBP-B that assist in glycan capture may similarly need to interact with their cognate TBDT in order to impart efficiency to the capture and uptake of glycans. For example, the SGBP-B encoded by the heparin-targeting PUL (PUL_{Hep}) of *B. thetaiotaomicron* has been shown to interact with the PUL_{Hep} SGBP-A, and this association may reflect an adaptive assembly for the capture of heparin near the TBDT [41].

In conclusion, this study describes roles for the *B. ovatus* GH9 and SGBP-B in the capture of XyG and possible modulation of the SGBP-A/TBDT complex that were previously unappreciated. The activities surrounding carbohydrate recognition by SGBPs and cell surface GHs are part of a fundamental nutrient acquisition paradigm in the gut Bacteroidetes that ultimately influences both the gut community composition and its collective metabolic activity. Further studies characterizing the interactions between these sets of proteins may facilitate the development of therapeutics to fine-tune carbohydrate catabolism by prominent gut bacteria to treat disease and promote health.

Materials and Methods

Bacterial strains and culture conditions

To generate all of the mutant XyGUL strains (Table 3), the *B. ovatus* ATCC-8483 Δtdk ($\Delta BACOVA_03071$) strain was employed to facilitate allelic exchange, as previously described [43,44], and is wild-type for the XyGUL. Mutations were generated using the counter-selectable allelic exchange vector pExchange-*tdk* [43]. The primers used in this study were synthesized by IDT DNA Technologies and are described in Supplemental Table 1. For site-directed mutagenesis of the BoGH9 gene, overlapping primers were designed to contain the mutation of interest within the pExchange vector, and then introduced into *B. ovatus* ATCC-8483 Δtdk ($\Delta BACOVA_03071$) via allelic exchange as described. Final mutations were confirmed by sequencing.

B. ovatus was cultured in a Coy anaerobic chamber (5% H₂/10% CO₂/85% N₂) from freezer stocks into tryptone-yeast extract-glucose medium [45], then passaged into Bacteroides MM including 5 mg/ml glucose (Sigma) as the sole carbon source prior to kinetic growth experiments on 5 mg/ml XyGO₁ (Megazyme), 5 mg/ml XyGO₂ (Megazyme), or 0.5–5 mg/ml Tamarind xyloglucan (Megazyme) [6]. MM-

glucose-grown overnight cultures were back-diluted 1:200 into parallel cultures of glucose and the test substrate to ensure that cultures started at the same relative O.D.₆₀₀ and to resolve differences in apparent lag before exponential growth. Kinetic growth experiments were performed at 37 °C in 96 well plates, and O.D.₆₀₀ was recorded every 10–30 min. All growth experiments were performed in triplicate.

Western blotting

B. ovatus strains were grown in MM containing 5 mg/ml glucose or xyloglucan and were harvested at O.D.₆₀₀ = 0.8. Cultures were normalized by O.D., and equal volumes of cells were lysed in SDS sample buffer and before being loading onto SDS-PAGE. SGBP-B and BoGH9 was detected in *B. ovatus* whole cell lysates by Western blot using custom rabbit polyclonal primary antibodies and horseradish peroxidase-conjugated goat anti-Rabbit IgG secondary antibody (Sigma) [44].

Recombinant gene cloning, expression, and protein purification

The gene encoding BoGH9 (*Bacova_02649*) amino acids 21–587 was PCR amplified from *B. ovatus* ATCC 8483 genomic DNA using the Q5 high-fidelity polymerase (NEB). The PCR product containing appropriate pMCSG complementary sequences was ligated in an Sspl-linearized pMCSG53 vector providing an N-terminal His₆-tag using Ligation Independent Cloning (LIC) strategy [46]. Successful cloning was confirmed by colony PCR (GoTaq polymerase from Promega) and sequencing (Genewiz).

The recombinant GH9 enzyme used in this study was produced in *Escherichia coli* BL21 (DE3) cells cultured in Terrific Broth containing ampicillin (50 µg/ml) at 37 °C (200 rpm). Cells were grown to mid-exponential growth phase (O.D.₆₀₀ ≈ 0.4 to 0.6). Overexpression was induced by adding IPTG to a final concentration of 0.5 mM, and the cultures were further grown at 16 °C (200 rpm) for 18 h. The cells were harvested by centrifugation and sonicated, and His₆-tagged recombinant proteins were purified using a HisTrap IMAC FF nickel-nitrilotriacetic acid column (GE Healthcare) utilizing a gradient elution up to 100% elution buffer containing 20 mM sodium phosphate (pH 7.4), 500 mM NaCl, and 500 mM imidazole in an BioLogic FPLC system (BioRad). The purity of the recombinant protein was determined by SDS/PAGE, and the identity of the expressed protein was confirmed by intact mass spectrometry [47]. Protein concentration was determined from the calculated molar extinction coefficient of 117370 M⁻¹ cm⁻¹ at 280 nm using an Epoch Microplate Spectrophotometer (BioTek). BoGH5A was purified as previously described [10].

Enzyme kinetic analysis

Polysaccharide hydrolysis was quantified using a bicinchoninic acid-reducing sugar assay as described previously [48] versus glucose standards (25–150 µM). To determine specific activity values of BoGH9 enzyme toward XyG, MLG, HEC, and CMC, a final concentration of 0.2164 µM of the recombinant purified enzyme was incubated with 1 mg/ml of polysaccharide in 200 µl reaction mixtures in 50 mM Hepes–NaOH buffer (pH 7.0). The effect of calcium ions on activity was determined by adding 1 mM CaCl₂ to the buffer reaction. Reaction mixtures were incubated at 37 °C for 25 min (MLG) or 30 min (XyG, HEC, CMC) prior to the bicinchoninic acid assay; all assays were performed in triplicate. The specific activity of BoGH5A enzyme toward XyG was determined by incubating triplicate reactions of 2.61 nM of the recombinant purified enzyme with 1 mg/ml of the polysaccharide in the optimum citrate buffer (pH 6.5) for 10 min at 37 °C.

Carbohydrate analytical method

HPAEC-PAD carbohydrate analysis was performed on a Dionex ICS-5000 HPLC system operated by Chromeleon software version 7 (Dionex Corp., Sunnyvale, CA, USA). The injection volume was 10 µl, and a Dionex Carbopac PA200 column (Thermo Scientific) with a guard column was used for all the samples separations. Solvent A was ultrapure water, solvent B was 1 M sodium hydroxide, and solvent C was 1 M sodium acetate prepared from anhydrous Bio Ultra-grade solid (Sigma). The following gradient was used: 0–5 min, 10% B and 3.5% solvent C; 5–12 min, 10% B and a linear gradient from 3.5% to 30% C; 12–12.1 min, 50% B, 50% C; 12.1–13 min, exponential gradient (curve setting 9) of B and C back to initial conditions; and 13–17 min, initial conditions [33].

To determine the mode of action of the enzyme, 3 µM of the recombinant enzyme was incubated with 0.25 mg/ml polysaccharide at 37 °C in a 0.5-ml reaction mixture containing 50 mM Hepes–NaOH buffer (pH 7.0) with 1 mM CaCl₂. The reaction was stopped at different time points by adding 100 µl of 95 °C water and heating to 95 °C for 10 min to a 100-µl aliquot of the reaction mixture. The reaction mixture was then diluted two times prior to product analysis by HPAEC-PAD.

BoGH9 crystallization and structure determination

The BoGH9 structure (res 27–583) presented here was determined via molecular replacement using a partially refined model, GH9-MR, obtained from crystals with translation lattice disorder and could not be completely refined. GH9-MR was expressed from the pET-YSBLLIC vector in BL21 Star (DE3) cells as

described for BoGH43A by Hemsworth *et al.* [14]. After growth, cells were pelleted via centrifugation and resuspended in Buffer A-His [50 mM Tris (pH 7.4), 0.5 M NaCl, 30 mM imidazole] and lysed via sonication. The lysate was clarified via centrifugation (38,000*g* for 30 min) and then applied to a 5-ml HisTrap FastFlow Ni-NTA column (GE Healthcare). A linear gradient of imidazole to a final concentration of 300 mM in Buffer A-His was used to elute the protein. Fractions containing the GH9-MR protein were pooled after inspection via SDS-PAGE and concentrated using a Sartorius 30 kDa MWCO concentrator. The concentrated sample was applied to a 16/60 Superdex 200 column pre-equilibrated with 10 mM Tris (pH 8.0) and 250 mM NaCl. Peak fractions were combined after inspection via SDS-PAGE and dialyzed into 10 mM Tris (pH 8.0) and 50 mM NaCl. Crystals of the GH9-MR were obtained via hanging drop vapor diffusion by mixing the protein (42 mg/ml with XyG₀₂) 1:1 with a crystallization solution composed of 0.1 M ammonium acetate, 0.1 M Bis-Tris (pH 5.5), and 10%–20% PEG 10,000. Crystals were flash-frozen in a cryo-protectant composed of mother liquor supplemented with 20% ethylene glycol, and x-ray data were collected at Diamond Light Source. The x-ray data were indexed and integrated with XDS [49] with all subsequent scaling and processing steps performed in CCP4 [50]. A partially built structure was obtained via molecular replacement in PHASER [51] using PDB ID 1CLC as the search model. Due to translational lattice disorder, the 1.7-Å model (residues 30–581) was not refined beyond $R_w = 29.4%$, $R_f = 34.9%$, but provided an excellent starting model for the structure for the final BoGH9 structure.

Hence, alternate crystals of BoGH9 were obtained from the Morpheus screen via hanging drop vapor diffusion at room temperature. BoGH9 protein (15.9 mg/ml) was mixed 1:1 with solution A2 [0.06 M MgCl₂ & CaCl₂, 0.1 M imidazole–MES buffer (pH 6.5), 30% mix of ethylene glycol, and PEG 8000]. Crystals were flash-frozen by plunging into liquid nitrogen and did not require additional cryoprotection. X-ray data were collected at the Life Sciences Collaborative Access Team beamline ID-F of the Advanced Photon Source at Argonne National Laboratory. Data were processed in HKL2000 and scaled with Scalepack [52]. Molecular replacement was performed in Phaser-MR [51] from the Phenix package [53] using the GH9MR structure as the search model, as described above. The final BoGH9 structure was refined with Phenix refine [54].

Accession numbers

The coordinates for the BoGH9 structure have been deposited in the PDB with the accession 6DHT.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jmb.2019.01.008>.

Acknowledgements

We thank the members of the Koropatkin and Martens laboratories at the University of Michigan for their support and advice during the design and execution of these studies. Research in Ann Arbor was provided by the National Institutes of Health (R01 GM118475 to N.M.K.). M.H.F. was partially supported by a predoctoral fellowship from the Cellular Biotechnology Training Program (T32GM008353). Research in Vancouver was supported by the Canadian Institutes of Health Research, the Canada Foundation for Innovation, and the British Columbia Knowledge Development Fund. Waters Corporation is gratefully acknowledged for the provision of the LC–MS system used in this study. G.J.D. is funded by the Royal Society through the Royal Society Ken Murray Professorship. G.J.D. and G.R.H. were supported by the Biotechnology and Biological Sciences Research Council (Grants BB/L021633/1 and BB/I014802/1).

Received 19 September 2018;

Received in revised form 14 December 2018;

Accepted 4 January 2019

Available online 19 January 2019

Keywords:

Bacteroidetes;
xyloglucan utilization locus;
polysaccharide utilization system;
Sus-like system;
lipoprotein

Present address: M.H. Foley, Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.

Present address: G.R. Hemsworth, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom.

Present address: G.R. Hemsworth, Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.

Abbreviations used:

GH, glycoside hydrolase; PUL, polysaccharide utilization loci; Sus, starch utilization system; TBDT, TonB-dependent transporter; SGBP, surface glycan-binding protein; XyGs, xyloglucans; XyGUL, xyloglucan utilization locus; HEC, hydroxyethylcellulose; CMC, carboxymethylcellulose; MM, minimal media; aTC, anhydrotetracycline.

References

- [1] T. Ding, P.D. Schloss, Dynamics and associations of microbial community types across the human body, *Nature* 509 (2014) 357–360.
- [2] E.C. Martens, E.C. Lowe, H. Chiang, N.A. Pudlo, M. Wu, N.P. McNulty, D.W. Abbott, B. Henrissat, H.J. Gilbert, D.N. Bolam, J.I. Gordon, Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts, *PLoS Biol.* 9 (2011), e1001221.
- [3] A. El Kaoutari, F. Armougom, J.I. Gordon, D. Raoult, B. Henrissat, The abundance and variety of carbohydrate-active enzymes in the human gut microbiota, *Nat. Rev. Microbiol.* 11 (2013) 497–504.
- [4] J.M. Grondin, K. Tamura, G. Dejean, D.W. Abbott, H. Brumer, polysaccharide utilization loci: fueling microbial communities, *J. Bacteriol.* 199 (2017).
- [5] J.L. Sonnenburg, J. Xu, D.D. Leip, C.H. Chen, B.P. Westover, J. Weatherford, J.D. Buhler, J.I. Gordon, Glycan foraging *in vivo* by an intestine-adapted bacterial symbiont, *Science* 307 (2005) 1955–1959.
- [6] E.C. Martens, H.C. Chiang, J.I. Gordon, Mucosal glycan foraging enhances fitness and transmission of a saccharolytic human gut bacterial symbiont, *Cell Host Microbe* 4 (2008) 447–457.
- [7] M.H. Foley, E.C. Martens, N.M. Koropatkin, SusE facilitates starch uptake independent of starch binding in *B. thetaiotaomicron*, *Mol. Microbiol.* 108 (2018) 551–566.
- [8] A.S. Tazuin, K.J. Kwiatkowski, N.I. Orlovsky, C.J. Smith, A.L. Creagh, C.A. Haynes, Z. Wawrzak, H. Brumer, N.M. Koropatkin, Molecular dissection of xyloglucan recognition in a prominent human gut symbiont, *MBio* 7 (2016) e02134-15.
- [9] E.D. Sonnenburg, H. Zheng, P. Joglekar, S.K. Higginbottom, S.J. Firbank, D.N. Bolam, J.L. Sonnenburg, Specificity of polysaccharide use in intestinal *Bacteroides* species determines diet-induced microbiota alterations, *Cell* 141 (2010) 1241–1252.
- [10] J. Larsbrink, T.E. Rogers, G.R. Hemsworth, L.S. McKee, A.S. Tazuin, O. Spadiut, S. Klinger, N.A. Pudlo, K. Urs, N.M. Koropatkin, A.L. Creagh, C.A. Haynes, A.G. Kelly, S.N. Cederholm, G.J. Davies, E.C. Martens, H. Brumer, A discrete genetic locus confers xyloglucan metabolism in select human gut *Bacteroidetes*, *Nature* 506 (2014) 498–502.
- [11] M. Hoffman, Z. Jia, M.J. Pena, M. Cash, A. Harper, A.R. Blackburn 2nd, A. Darvill, W.S. York, Structural analysis of xyloglucans in the primary cell walls of plants in the subclass *Asteridae*, *Carbohydr. Res.* 340 (2005) 1826–1840.
- [12] Y.S. Hsieh, P.J. Harris, Xyloglucans of monocotyledons have diverse structures, *Mol. Plant* 2 (2009) 943–965.
- [13] M. Pauly, K. Keegstra, Biosynthesis of the plant cell wall matrix polysaccharide xyloglucan, *Annu. Rev. Plant Biol.* 67 (2016) 235–259.
- [14] G.R. Hemsworth, A.J. Thompson, J. Stepper, L.F. Sobala, T. Coyle, J. Larsbrink, O. Spadiut, E.D. Goddard-Borger, K.A. Stubbs, H. Brumer, G.J. Davies, Structural dissection of a complex *Bacteroides ovatus* gene locus conferring xyloglucan metabolism in the human gut, *Open Biol.* 6 (2016).
- [15] A. Rogowski, J.A. Briggs, J.C. Mortimer, T. Tryfona, N. Terrapon, E.C. Lowe, A. Basle, C. Morland, A.M. Day, H. Zheng, T.E. Rogers, P. Thompson, A.R. Hawkins, M.P. Yadav, B. Henrissat, E.C. Martens, P. Dupree, H.J. Gilbert, D.N. Bolam, Glycan complexity dictates microbial resource allocation in the large intestine, *Nat. Commun.* 6 (2015) 7481.
- [16] H.H. Tuson, M.H. Foley, N.M. Koropatkin, J.S. Biteen, The starch utilization system assembles around stationary starch-binding proteins, *Biophys. J.* 115 (2018) 242–250.
- [17] A.J. Glenwright, K.R. Pothula, S.P. Bhamidimarri, D.S. Chorev, A. Basle, S.J. Firbank, H. Zheng, C.V. Robinson, M. Winterhalter, U. Kleinekathofer, D.N. Bolam, B. van den Berg, Structural basis for nutrient acquisition by dominant members of the human gut microbiota, *Nature* 541 (2017) 407–411.
- [18] L. Holm, C. Sander, Dali: a network tool for protein structure comparison, *Trends Biochem. Sci.* 20 (1995) 478–480.
- [19] A. Correa, S. Pacheco, A.E. Mechaly, G. Obal, G. Behar, B. Mouratou, P. Oppezzo, P.M. Alzari, F. Pecorari, Potent and specific inhibition of glycosidases by small artificial binding proteins (affitins), *PLoS One* 9 (2014), e97438.
- [20] K. Eckert, A. Vigouroux, L. Lo Leggio, S. Morera, Crystal structures of *A. acidocaldarius* endoglucanase Cel9A in complex with cello-oligosaccharides: strong –1 and –2 subsites mimic cellobiohydrolase activity, *J. Mol. Biol.* 394 (2009) 61–70.
- [21] K. Eckert, F. Zielinski, L. Lo Leggio, E. Schneider, Gene cloning, sequencing, and characterization of a family 9 endoglucanase (CelA) with an unusual pattern of activity from the thermoacidophile *Alicyclobacillus acidocaldarius* ATCC27009, *Appl. Microbiol. Biotechnol.* 60 (2002) 428–436.
- [22] J. Peng, W. Wang, Y. Jiang, M. Liu, H. Zhang, W. Shao, Enhanced soluble expression of a thermostable cellulase from *Clostridium thermocellum* in *Escherichia coli*, *Curr. Microbiol.* 63 (2011) 523–530.
- [23] E.A. Bayer, Y. Shoham, R. Lamed, Cellulose-decomposing prokaryotes and their enzyme systems, in: M. Dworkin, S. Falkow, E. Rosenberg, K.-H. Schleifer, E. Stackebrandt (Eds.), *The Prokaryotes: An Involving Electronic Resource for the Microbial Community*, vol. 2, Springer Verlag, New York, NY, 2000.
- [24] S. Chauvaux, H. Souchon, P.M. Alzari, P. Chariot, P. Beguin, Structural and functional analysis of the metal-binding sites of *Clostridium thermocellum* endoglucanase CelD, *J. Biol. Chem.* 270 (1995) 9757–9762.
- [25] Y.K. Li, L.D. Byers, Inhibition of beta-glucosidase by imidazoles, *Biochim. Biophys. Acta* 999 (1989) 227–232.
- [26] R.A. Field, A.H. Haines, E.J. Chrystal, M.C. Luszniak, Histidines, histamines and imidazoles as glycosidase inhibitors, *Biochem. J.* 274 (Pt 3) (1991) 885–889.
- [27] K. Tamura, G.R. Hemsworth, G. Dejean, T.E. Rogers, N.A. Pudlo, K. Urs, N. Jain, G.J. Davies, E.C. Martens, H. Brumer, Molecular mechanism by which prominent human gut *Bacteroidetes* utilize mixed-linkage beta-glucans, major health-promoting cereal polysaccharides, *Cell Rep.* 21 (2017) 417–430.
- [28] B. Lim, M. Zimmermann, N.A. Barry, A.L. Goodman, Engineered regulatory systems modulate gene expression of human commensals in the gut, *Cell* 169 (2017) 547–558 (e15).
- [29] B.R. Hamaker, Y.E. Tuncil, A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota, *J. Mol. Biol.* 426 (2014) 3838–3850.
- [30] N.M. Koropatkin, E.A. Cameron, E.C. Martens, How glycan metabolism shapes the human gut microbiota, *Nat. Rev. Microbiol.* 10 (2012) 323–335.
- [31] L.A. David, C.F. Maurice, R.N. Carmody, D.B. Gootenberg, J.E. Button, B.E. Wolfe, A.V. Ling, A.S. Devlin, Y. Varna, M.A. Fischbach, S.B. Biddinger, R.J. Dutton, P.J. Turnbaugh, Diet rapidly and reproducibly alters the human gut microbiome, *Nature* 505 (2014) 559–563.

- [32] N. Natarajan, J.L. Pluznick, From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology, *Am. J. Physiol. Cell Physiol.* 307 (2014) C979–C985.
- [33] J.M. Eklof, M.C. Ruda, H. Brumer, Distinguishing xyloglucanase activity in endo-beta(1 → 4)glucanases, *Methods Enzymol.* 510 (2012) 97–120.
- [34] J. Ravachol, R. Borne, C. Tardif, P. de Philip, H.P. Fierobe, Characterization of all family-9 glycoside hydrolases synthesized by the cellulosome-producing bacterium *Clostridium cellulolyticum*, *J. Biol. Chem.* 289 (2014) 7335–7348.
- [35] M.A. Attia, H. Brumer, Recent structural insights into the enzymology of the ubiquitous plant cell wall glycan xyloglucan, *Curr. Opin. Struct. Biol.* 40 (2016) 43–53.
- [36] E.C. Martens, A.G. Kelly, A.S. Tausin, H. Brumer, The devil lies in the details: how variations in polysaccharide fine-structure impact the physiology and evolution of gut microbes, *J. Mol. Biol.* 426 (2014) 3851–3865.
- [37] E.A. Bayer, R. Lamed, B.A. White, H.J. Flint, From cellulosomes to cellulosomes, *Chem. Rec.* 8 (2008) 364–377.
- [38] J. Ravachol, P. de Philip, R. Borne, P. Mansuelle, M.J. Mate, S. Perret, H.P. Fierobe, Mechanisms involved in xyloglucan catabolism by the cellulosome-producing bacterium *Ruminiclostridium cellulolyticum*, *Sci. Rep.* 6 (2016), 22770.
- [39] A.B. Boraston, D.N. Bolam, H.J. Gilbert, G.J. Davies, Carbohydrate-binding modules: fine-tuning polysaccharide recognition, *Biochem. J.* 382 (2004) 769–781.
- [40] M.H. Foley, D.W. Cockburn, N.M. Koropatkin, The Sus operon: a model system for starch uptake by the human gut Bacteroidetes, *Cell. Mol. Life Sci.* 73 (2016) 2603–2617.
- [41] A. Cartmell, E.C. Lowe, A. Basle, S.J. Firbank, D.A. Ndeh, H. Murray, N. Terrapon, V. Lombard, B. Henrissat, J.E. Turnbull, M. Czjzek, H.J. Gilbert, D.N. Bolam, How members of the human gut microbiota overcome the sulfation problem posed by glycosaminoglycans, *Proc. Natl. Acad. Sci. U. S. A.* 114 (2017) 7037–7042.
- [42] E.A. Cameron, K.J. Kwiatkowski, B.H. Lee, B.R. Hamaker, N.M. Koropatkin, E.C. Martens, Multifunctional nutrient-binding proteins adapt human symbiotic bacteria for glycan competition in the gut by separately promoting enhanced sensing and catalysis, *MBio* 5 (2014) e01441-14.
- [43] N.M. Koropatkin, E.C. Martens, J.I. Gordon, T.J. Smith, Starch catabolism by a prominent human gut symbiont is directed by the recognition of amylose helices, *Structure* 16 (2008) 1105–1115.
- [44] E.A. Cameron, M.A. Maynard, C.J. Smith, T.J. Smith, N.M. Koropatkin, E.C. Martens, Multidomain carbohydrate-binding proteins involved in *Bacteroides thetaiotaomicron* starch metabolism, *J. Biol. Chem.* 287 (2012) 34614–34625.
- [45] L.V. Holdeman, E.D. Cato, W.E.C. Moore, in: W.E.C. Moore (Ed.), *Anaerobe Laboratory Manual*, Virginia Polytechnic Institute and State University Anaerobe Laboratory, Blacksburg, VA, 1977.
- [46] W.H. Eschenfeldt, S. Lucy, C.S. Millard, A. Joachimiak, I.D. Mark, A family of LIC vectors for high-throughput cloning and purification of proteins, *Methods Mol. Biol.* 498 (2009) 105–115.
- [47] G. Sundqvist, M. Stenvall, H. Berglund, J. Ottosson, H. Brumer, A general, robust method for the quality control of intact proteins using LC-ESI-MS, *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 852 (2007) 188–194.
- [48] G. Arnal, M.A. Attia, J. Asohan, H. Brumer, A low-volume, parallel copper-bicinchoninic acid (BCA) assay for glycoside hydrolases, *Methods Mol. Biol.* 1588 (2017) 3–14.
- [49] W. Kabsch, Integration, scaling, space-group assignment and post-refinement, *Acta Crystallogr. D Biol. Crystallogr.* 66 (2010) 133–144.
- [50] R.A. Othman, M.H. Moghadasian, P.J. Jones, Cholesterol-lowering effects of oat beta-glucan, *Nutr. Rev.* 69 (2011) 299–309.
- [51] A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, R.J. Read, Phaser crystallographic software, *J. Appl. Crystallogr.* 40 (2007) 658–674.
- [52] Z. Otwinowski, W. Minor, [20] processing of X-ray diffraction data collected in oscillation mode, *Methods Enzymol.* 276 (1997) 307–326.
- [53] P.D. Adams, P.V. Afonine, G. Bunkoczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.-W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, A.J. McCoy, N.W. Moriarty, R. Oeffner, R.J. Read, D.C. Richardson, J.S. Richardson, T.C. Terwilliger, P.H. Zwart, PHENIX: a comprehensive Python-based system for macromolecular structure solution, *Acta Crystallogr. D Biol. Crystallogr.* 66 (2010) 213–221.
- [54] P.V. Afonine, R.W. Grosse-Kunstleve, N. Echols, J.J. Headd, N.W. Moriarty, M. Mustyakimov, T.C. Terwilliger, A. Urzhumtsev, P.H. Zwart, P.D. Adams, Towards automated crystallographic structure refinement with phenix.refine, *Acta Crystallogr. D Biol. Crystallogr.* 68 (2012) 352–367.
- [55] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, UCSF Chimera—a visualization system for exploratory research and analysis, *J. Comput. Chem.* 25 (2004) 1605–1612.